Skip to content
Blackwells-Logo-White2
  • About Us
    • Our Approach
    • Leadership
    • ESG
  • Our Businesses
    • Public Markets
    • Private Equity & Venture Capital
    • Real Estate & Credit
  • News
  • Careers
  • Contact Us
  • Search

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

By Kelly Mitten | January 6, 2025
Read More

Star Therapeutics raises $90m in funding to advance antibody therapies

By Blackwells Capital | September 5, 2023
Read More

Star Therapeutics adds another $90M to grow its galaxy of drug startups

By Blackwells Capital | September 5, 2023
Read More

Investors shower Star Therapeutics with $90M for constellation of biotechs, antibody therapies

By Blackwells Capital | September 5, 2023
Read More

Recent Posts

  • Leading Semiconductor Company Taps Articul8 to Accelerate Product Release Cycles with Domain-Specific GenAI
  • Rheinmetall, ICEYE partner on $2 billion German army order for space sector
  • 24X National Exchange Welcomes Strategic Equity Investment from Shinhan Securities of Korea
  • Accton/Edgecore, 1Finity, and Liqid Collaborate to Deliver Seamless All-Photonic Datacenter Connectivity with Composable High Performance and Wide-Area Resource Sharing
  • Finland backs space tech ICEYE firm with R&D funding

CONTACT INFORMATION

NEW YORK

400 Park Avenue
4th Floor
New York, NY 10022
Phone: +1 212-792-6096

MONTREAL

7075 Robert Joncas Place
Suite 411
Saint-Laurent, QC H4M 2Z5
Phone: +1 514-375-3762

MEDIA INQUIRIES

GAGNIER COMMUNICATIONS
Dan Gagnier
blackwells@gagnierfc.com

 

© 2026 Blackwells Capital, All Rights Reserved.  Privacy Policy | Terms of Use | Disclaimer